LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)
SEONGNAM, South Korea, March 29, 2024 /PRNewswire/ -- LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and
Kyonggi Do South Korea Liscure Biosciences Jiyoung Ahn Head Of Clinical Development Drug Administration
Source: thailand-business-news.com